Viking Therapeutics (NasdaqCM:VKTX) 2026 Conference Transcript

Viking Therapeutics Conference Call Summary Company Overview - Company: Viking Therapeutics (NasdaqCM: VKTX) - Industry: Biotechnology, specifically focused on obesity treatments Key Points and Arguments 2025 Achievements and 2026 Outlook - 2025 Accomplishments: - Initiated registration program for dual agonist VK2735 with two Phase 3 trials, VANQUISH-1 and VANQUISH-2, which began mid-year and showed rapid enrollment [9][10] - Phase 2 data for oral formulation demonstrated a favorable profile, leading to plans for Phase 3 initiation in Q3 2026 [10] - 2026 Expectations: - Anticipation of significant data readouts in Q3 2026, particularly from the maintenance study transitioning patients from weekly to monthly dosing [10][11] Enrollment and Investigator Interest - Rapid enrollment in VANQUISH-1 and VANQUISH-2 attributed to high enthusiasm for weight loss therapies and strong investigator attendance at meetings [14][15] Auto-Injector Development - Bioequivalence study completed for the auto-injector, which will be incorporated into the VANQUISH program, allowing for a transition from vial and syringe to auto-injector [16][17] Dosing and Titration Schedule - Phase 3 dosing starts at 1.25 mg for 2 weeks, with increments every 4 weeks, reaching a maximum of 17.5 mg over 26 weeks [18][19] Weight Loss Expectations - Previous Phase 2 data indicated approximately 15% weight loss at the 15 mg dose over 13 weeks, with expectations to be competitive against existing therapies [22][25] Safety and Tolerability - Initial GI-related side effects expected to diminish after the first 4-6 weeks, with a focus on improving tolerability through a gradual titration schedule [28] Competitive Profile - VK2735 has a longer half-life (8-9 days) compared to competitors, potentially leading to improved efficacy and a more convenient dosing regimen [31][32] Commercial Strategy - Viking Therapeutics aims for a 5%-10% market share to be successful, leveraging its nimbleness compared to larger competitors [40][41] - Plans to target both the cash pay market and international opportunities, with a focus on aggressive marketing strategies [40][41] Pricing Strategy - Differentiation between list price and net price reductions is emphasized, with expectations for price stability in a duopoly market [46][47] Oral Program Insights - Phase 2 VENTURE oral study showed a maximum weight loss of 12.2%, with plans to initiate Phase 3 studies in Q3 2026 [53][55] - The oral program is expected to be more cost-effective than the subQ program, with a smaller trial size and reduced visit frequency [56][57] Maintenance Study Design - The maintenance study will evaluate both subQ and oral dosing regimens, with various cohorts transitioning from weekly to monthly or every other week dosing [75][76] Amylin Program Development - Viking is advancing an amylin program, with initial studies planned to assess its efficacy in weight loss, targeting specific patient populations [90][92] Manufacturing Capacity - A manufacturing supply agreement with Catalent ensures sufficient capacity for commercial supply, covering a multi-ton annual API supply [86][87] Additional Important Insights - The market for obesity treatments is expected to become increasingly segmented, with different patient preferences for dosing frequency and administration routes [83][84] - Viking Therapeutics is positioned to leverage its unique product profile and clinical data to capture market share in a competitive landscape [40][41]